Search Results

NCDR Analysis Compares Effectiveness of Commonly Used CAS Devices

January 15, 2014—Jay Giri, MD, et al published findings from a National Cardiovascular Data Registry (NCDR) analysis that evaluated the comparative effectiveness of commonly used devices for carotid artery stenting (CAS).

ELEGANCE Registry Studies Drug-Eluting Device Treatment of PAD in Underrepresented Minorities and Women

November 5, 2024—The ELEGANCE registry, which is focused on historically underrepresented minorities and women, analyzed endovascular treatment of peripheral artery disease (PAD) with drug-eluting devices.

Study Compares Embolic Protection Devices Used in CAS

April 20, 2015—The American College of Cardiology (ACC) announced that a study showing that in-hospital and 30-day stroke or death rates were equally low when using either a distal filter embolic protection device (F-EPD) or a proximal device (P-EPD) to protect patients from blood clots during carotid artery stenting (CAS) was published by Jay Giri, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions (2015;8:609–615).

Inari PEERLESS II RCT Will Compare FlowTriever Versus Anticoagulation in PE Patients

May 22, 2023—Inari Medical, Inc. announced the planned enrollment of PEERLESS II, the company’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).

Endovascular Engineering’s Helo Thrombectomy System for PE Studied in ENGULF

November 7, 2023—Endovascular Engineering, Inc. (E2) announced recently that initial results from its ENGULF study demonstrated successful outcomes among the first 15 patients evaluated in the trial using E2’s Helo thrombectomy system for the treatment of acute submassive pulmonary embolism (PE).

Endovascular Engineering’s Helo Thrombectomy System Receives IDE Approval for ENGULF Pivotal Trial to Treat PE

January 11, 2024—Endovascular Engineering (E2), a developer of clot removal technologies for venous thromboembolism, announced FDA approval for an investigational device exemption (IDE) for the ENGULF United States pivotal trial.

Inari Commences PEERLESS II RCT of FlowTriever in Intermediate-Risk PE

November 27, 2023—Inari Medical, Inc. announced that the the first patient has been enrolled in the PEERLESS II randomized controlled trial (RCT).

Endovascular Engineering Helo Thrombectomy System for Acute PE Evaluated in ENGULF Trial

May 3, 2024—Late-breaking data from the ENGULF trial showed that the dual-action Helo pulmonary embolism (PE) thrombectomy system (Endovascular Engineering [E2]) was effective and safe in treating acute PE.

No Evidence of Paclitaxel-Related Increased Mortality Found in Medicare Database Analysis at 600 Days

February 14, 2019—A study published online in JAMA Cardiology by Eric A. Secemsky, MD, et al showed no evidence of increased all-cause mortality following femoropopliteal artery revascularization using paclitaxel drug-eluting stents (DESs) or drug-coated balloons (DCBs) versus non–drug-coated devices. The study seeks to explore concerns raised by the meta-analysis by Katsanos et al regarding the potential for increased mortality associated with the use of paclitaxel in patients with peripheral artery disease.